Skip to main content
Premium Trial:

Request an Annual Quote

Correlogic and Matsui Renew Japanese Cancer Partnership

NEW YORK (GenomeWeb News) — Clinical proteomics company Correlogic Systems today said it has renewed a research collaboration and signed a new agreement with Japanese company Mitsui.
 
The new deal extends a relationship begun in 2004 when the companies signed an exploratory agreement to use Correlogic's pattern-recognition approach and technology to detect ovarian cancer in Japanese women. 
 
Correlogic said the new agreement marks the conclusion of that "mini-trial" and said the two companies will now continue to develop pattern-recognition tests for ovarian and other cancers that are prevalent in Japan.
 
Japanese pharmaceutical company Quintiles Japan will help the companies select samples and conduct more trials. 
 
Financial details of the new agreement were not disclosed.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.